Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients

Journal of Hospital Infection

Volumn 78, Issue 1, 2011, Pages 54-58

  Orsi, G B ^a   Garcia Fernandez A ^b   Giordano, A ^a   Venditti, C ^b   Bencardino, A ^a   Gianfreda, R ^a   Falcone, M ^a   Carattoli, A ^b   Venditti, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Ertapenem resistance; Klebsiella pneumoniae; Risk factors

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CEPHALOSPORIN; DAPTOMYCIN; ERTAPENEM; IMIPENEM; LINEZOLID; MEROPENEM; OUTER MEMBRANE PROTEIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PORIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN;

ABDOMINAL INFECTION; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BLOODSTREAM INFECTION; CONTROLLED STUDY; ENDOSCOPY; ERTAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; FEMALE; GENE EXPRESSION; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MULTILOCUS SEQUENCE TYPING; RISK ASSESSMENT; SEPTICEMIA; SURGICAL INFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL TYPING TECHNIQUES; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CLUSTER ANALYSIS; FEMALE; GENOTYPE; HOSPITALIZATION; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; PORINS; RISK FACTORS; TREATMENT OUTCOME;

EID: 79954598745     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2011.01.014     Document Type: Article

References (34)

1. Falagas M.E., Rafailidis P.I., Kofteridis D., et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case-control study. J Antimicrob Chemother 2007, 60:1124-1130.
2. Nordmann P., Cuzon G., Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9:228-236.
3. Jacoby G.A., Munoz-Price L.S. The new beta-lactamases. N Engl J Med 2005, 352:380-391.
4. MacKenzie F.M., Forbes K.J., Dorai-John T., Amyes S.J., Gould I.M. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet 1997, 350:783.
5. Livermore D.M. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Invest Drugs 2002, 3:218-224.
6. Walsh T.R., Toleman M.A., Poirel L., Nordmann P. Metallo-beta-lactamases: the quiet before the storm?. Clin Microbiol Rev 2005, 18:306-325.
7. Elliott E., Brink A.J., van Greune J., et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006, 42:e95-e98.
8. Gröbner S., Linke D., Schütz W., et al. Emergence of carbapenem-non-susceptible extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tubingen, Germany. J Med Microbiol 2009, 58:912-922.
9. Leavitt A., Chmelnitsky I., Colodner R., Ofek I., Carmeli Y., Navon-Venezia S. Ertapenem resistance among extended-spectrum-β-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol 2009, 47:969-974.
10. Mena A., Plasencia V., García L., et al. Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol 2006, 44:2831-2837.
11. Doménech-Sánchez A., Martínez-Martínez L., Hernández-Allés S., et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother 2003, 47:3332-3335.
12. Doumith M., Ellington M.J., Livermore D.M., Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009, 63:659-667.
13. Jacoby G.A., Mills D.M., Chow N. Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004, 48:3203-3206.
14. Wang X.D., Cai J.C., Zhou H.W., Zhang R., Chen G.X. Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated beta-lactamases production and OmpK36 porin deficiency. J Med Microbiol 2009, 58:1196-1202.
15. García-Fernández A., Miriagou V., Papagiannitsis C.C., Giordano A., Venditti M., Mancini C., Carattoli A. An ertapenem-resistant ESBL-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Antimicrob Agents Chemother 2010, 54:4178-4184.
16. Borer A., Saidel-Odes L., Riesenberg K., et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009, 30:972-976.
17. Gasink L.B., Adelstein P.H., Lautenbach E., Synnestvedt M., Fishman N.O. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009, 30:1180-1185.
18. Hussein K., Sprecher H., Mashiach T., Oren I., Kassis I., Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics and susceptibility patterns. Infect Control Hosp Epidemiol 2009, 30:666-671.
19. Kwak Y.G., Choi S.H., Choo E.J., et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005, 11:165-169.
20. Schwaber M.J., Klarfeld-Lidji S., Navon-Venezia S., Schwartz D., Leavitt A., Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008, 52:1028-1033.
21. Diancourt L., Passet V., Verhoef J., Grimont P.A., Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 2005, 43:4178-4182.
22. Charlson M.E., Pompei P., Ales K.L., MacKenzie R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
23. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. CDC definitions for nosocomial infections. APIC infection control and applied epidemiology: principles and practice 1993, Mosby, St Louis, p. A-1-A-20.
24. Gilbert D.N., Moellering R.C., Eliopoulos G.M., Chambers H.F., Saag M.S. The Sanford guide to antimicrobial therapy 2009 2009, Antimicrobial Therapy, Inc., Sperryville, VA. 39th ed.
25. Patel G., Huprikar S., Factor S.H., Jenkins S.G., Calfee D.P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106.
26. Naas T., Cuzon G., Babics A., et al. Endoscopy-associated transmission of carbapenem-resistant Klebsiella pneumoniae producing KPC-2 B-lactamase. J Antimicrob Chemother 2010, 65:1305-1306.
27. Pitout J.D.D., Laupland K.B. Extended-spectrum beta-lactamase producing enterobacteriaceae; an emerging public health concern. Lancet Infect Dis 2008, 8:159-166.
28. Bratu S., Mooty M., Nichani S., et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005, 49:3018-3020.
29. Tenover F.C., Kalsi R.K., Williams P.P., et al. Carbapenem-resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006, 12:1209-1213.
30. Anderson K.F., Lonsway D.R., Rasheed J.K., et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007, 45:2723-2725.
31. Falcone M., Menatesta M.L., Perilli M., et al. Infections with VIM-1 metallo-(beta)-lactamase-producing Enterobacter cloacae and their correlation with clinical outcome. J Clin Microbiol 2009, 47:3514-3519.
32. Chia J.H., Su L.H., Lee M.H., et al. Development of high level carbapenem resistance in Klebsiella pneumoniae among patients with prolonged hospitalization and carbapenem exposure. Microbiol Drug Resist 2010, 16:317-325.
33. Song W., Suh B., Choi J.Y., et al. In vivo selection of carbapenem-resistant Klebsiella pneumoniae by OmpK36 loss during meropenem treatment. Diagn Microbiol Infect Dis 2009, 65:447-449.
34. Harris A.D., Karchmer T.B., Carmeli Y., Samore M.H. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001, 32:1055-1061.